跳至主要内容
临床试验/CTRI/2023/05/053228
CTRI/2023/05/053228已完成不适用

Clinical Investigation of the WaveLight® UV Femtosecond Laser Lenticle Extraction Sphere Nomogram

Alcon Laboratories Inc2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2023年7月20日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
45
试验地点
2
主要终点
Evaluate achieved spherical manifest refraction at post operative follow up visits.

研究概览

简要总结

Summary:

The WaveLight® Ultraviolet Femtosecond Laser System, Model 1026 (UV fs-Laser) with accompanying Patient Interface, Model 1507 has been developed to provide an alternative refractive surgery option that uses UV light with a wavelength of 347 nm instead of IR light. The UV-Femtosecond Laser Assisted Lenticular Extraction procedure creates canals in the cornea and an intrastromal lenticule which, when removed, provides the refractive error correction.

This is an interventional, prospective, single-arm, single-eye, unmasked, multi-center clinical study. This study uses a femtosecond laser with UV radiation. The UV fs-Laser has been used in human subjects in three studies: one first-in-human early feasibility study has been completed, another feasibility study for the UV fs-Laser lenticule extraction procedure is ongoing, and another refractive procedure study using the UV fs-Laser to create a corneal flap for LASIK is also ongoing. The goal of this trial is to collect data on the safety and effectiveness of the sphere nomogram component of the UV fs-Laser when using the lenticule extraction procedure in a patient population that is distributed across three sphere diopter treatment groups.

Brief Summary after completion:

37 subjects were enrolled, of whom 31 were exposed to the test device, and 30 completed the study

Subjects in this study had an overall mean age of 26.7 years, with 36.7% female subjects in the study as compared to 63.3% male subjects. Subjects self-identified predominantly as Asian and Not Hispanic or Latino.

Primary Effectiveness: The mean spherical manifest refraction at Screening was -4.158 D. The mean spherical manifest refraction measurements improved as early as Week 1 postoperative (-0.683 D) and remained stable at all postoperative visits, including Month 6 postoperative (-0.707 D).

Primary Safety: The mean BCDVA at Screening was -0.047 logMAR. The mean BCDVA was similar at all postoperative visits, including Month 6 postoperative (-0.015 logMAR). The percentage for change in BCDVA was reported as > 2 lines worse in 1 subject at Week 1 (3.2%), Month 3 (3.2%), and Month 6 (3.3%) postoperative.

Ocular SAEs for study eyes were reported in 3 subjects (9.7%). There were 4 total events reported (1 each) of corneal endothelial cell loss greater than 10% from preoperative (1, 3.2%), corneal infiltrates (1, 3.2%), corneal opacity (1, 3.2%), and ocular procedural complication (1, 3.2%).

Overall, the treatment and accuracy of the sphere lenticule nomogram (treatment calculation algorithm) of the UV fs-Laser across the allowed dioptric range in subjects with no or low cylinder were safe. The overall results showed that the UV fs-Laser reduced spherical refractive error. However, the results of this study warrant further investigation into methods for reducing variability in treatment outcomes, particularly for higher dioptric treatments.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Participants will include male and female subjects 18 years of age or older, with good ocular health, diagnosed with myopia in the study eye with manifest refraction sphere of -0.50 to -10.0 D and cylinder < -0.5 D.
  • Subjects must have no evidence of cataract or prior ocular surgeries in the study eye.

排除标准

  • Subjects will be excluded if the eye to be treated is unable to focus for imaging and/or treatment, has a predicted residual stromal bed thickness <250 μm, or if the subject has any acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study or are using any contraindicated medications.

结局指标

主要结局

Evaluate achieved spherical manifest refraction at post operative follow up visits.

时间窗: Day 01 Week 01 Month 01 month 03 Month 06

次要结局

  • Cylinder manifest refraction, UCDVA and MRSE at(postoperative follow-up visits)

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (2)

Loading locations...

相似试验